Global Cell Line Development Market 2023-2030

Global Cell Line Development Market 2023-2030

Global Cell Line Development Market Size, Share & Trends Analysis Report by Product Type (Reagent and Media, Equipment and Accessories and Consumables), by Source Type (Mammalian and Non-mammalian), by End User (Biopharmaceutical and Biotechnology Companies, Contract Research Organizations and Academics and Research Institutes) and by Cell Line (Recombinant, Hybridomas, Continuous and Primary), Forecast Period (2023-2030)

The global Cell Line Development market is anticipated to grow at a CAGR of 9.6% during the forecast period (2023-2030). Cell line development is a critical process in biotechnology and pharmaceutical research, aimed at creating stable and high-yielding cell lines to produce therapeutic proteins, antibodies, vaccines, and other biopharmaceuticals. The initial step involves choosing a suitable host cell line, often derived from mammalian, insect, or microbial sources, depending on the specific requirements of the product.

Segmental Outlook

The global Cell Line Development market is segmented on the product type, Source type, End user, and cell line. Based on the product type, the market is sub-segmented into Reagent and Media, Equipment and Accessories and Consumables. Based on source type, the market is sub-segmented into Mammalian and Non-mammalian. Based on the end user, the market is sub-segmented into Biopharmaceutical and Biotechnology Companies, Contract Research Organizations and Academics and Research Institutes. And based on cell line, the market is segmented into Recombinant, Hybridomas, Continuous and Primary. Among the cell line, the Recombinant sub-segment is anticipated to hold a considerable share of the market, owing to rising demand for biologics to treat cancer and autoimmune illnesses.

The Mammalian Sub-Segment is Anticipated to Hold a Considerable Share of the Global Cell Line Development Market

Among the Source Type, the Mammalian sub-segment is expected to hold a considerable share of the global Cell Line Development market. This segmental growth is attributed to several factors such as, mammalian cell sources are being used to create monoclonal antibodies. These cell lines produce intricate proteins that are reminiscent of those in the human body, aiding in the creation of customized medications. Additionally, human tissues and other biological components can easily adapt to mammalian cell lines, lowering the risk of infection. For instance, In June 2023, Synthego, announced a groundbreaking partnership with ATCC, the premier non-profit global biological materials and standards resource center, to provide researchers with an extensive collection of mammalian and mouse cell lines for gene editing applications, including Express Cell Pools to increase speed to results. This alliance brings together its expertise in genome engineering and ATCC's renowned reputation as a trusted provider of authenticated biological materials and standards.

Regional Outlook

The global Cell Line Development market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to improving healthcare infrastructure, and favorable initiatives by government in the region.

The North America Region is Expected to Grow at a Significant CAGR in the Global Cell Line Development Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to improving medical infrastructure and increasing strategic initiatives by market players for better research and product development in the regions. For instance, in September 2023, Lineage Cell Therapeutics, Inc., announced the initiation of certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the Company’s exclusive option and license agreement with Eterna Therapeutics Inc. This marks the next step under the strategic collaboration announced in February 2023, under which Eterna is developing innovative engineered hypoimmune iPSC lines that Lineage will evaluate for differentiation into cell transplant product candidates for central nervous system (CNS) diseases and other neurology indications. Since announcing the deal earlier, Lineage has evaluated its development strategy with a group of leading neurology experts in the US and abroad. As a result of these and other discussions, and an assessment of the competitive landscape, Lineage finalized its selection of specific gene edits for the initial cell lines to be developed by Eterna. The edits include the targeted deletion of the B2M gene, designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8+ T cells; the targeted insertion of the HLA-E gene, designed to overexpress HLA-E and prevent the allogeneic NK cell response, and a third undisclosed edit intended to confer clinical differentiation and a competitive advantage in the applicable indications. Lineage expects that these edits would expand the edited cell lines’ overall utility, including for non-immune privileged or non-human leukocyte antigen (HLA) matched indications and will further differentiate the cell line from others currently in use by competitors.

Market Players Outlook

The major companies serving the Cell Line Development market include Advanced Instruments, Berkeley Lights, Boehringer Ingelheim International GmbH, Creative BioLabs., Danaher, Fujifilm Holdings Corp, Horizon Discovery Ltd., JSR Corp, Lonza, Merck KGaA Corning Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2019, Solentim, the cell line development (CLD) imaging instrumentation producer, and SAL Scientific, a provider of growth-enhancing animal-free cell culture reagents, announced a new strategic partnership. The collaboration will further optimise CLD workflow by supplying novel supplements which substantially improve cell growth. Solentim will act as the exclusive distributor for the SAL Scientific ‘Insti’ product range. Cells grown in chemically defined, animal component-free media can be susceptible to impaired growth and viability, especially when subjected to stress.

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Cell Line Development market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.